Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether. The disease is a clinical syndrome characterized by albuminuria, decline in glomerular filtration rate, and elevated arterial blood pressure. Up to 50% of diabetics with a disease duration of over 20 years have diabetic nephropathy.
- An ADA/EASD consensus report will help spur use of SGLT-2 inhibitors in DN patients.
- Survey of 216 physicians in the US, Japan, and five major EU markets sheds light on prescribing patterns.
- In parallel with diabetes, an increase in the prevalence burden of diabetic nephropathy cases is expected during 2017–37.
- In-depth analysis of drug classes used for the treatment of diabetic nephropathy in the US, Japan, and five major EU markets.
- Drugs with a cardiovascular benefit will have an advantage in DN.